Tudor Investment Corp ET AL Takes $625,000 Position in Vericel Corporation $VCEL

Tudor Investment Corp ET AL bought a new position in shares of Vericel Corporation (NASDAQ:VCEL) during the 3rd quarter, HoldingsChannel reports. The fund bought 19,854 shares of the biotechnology company’s stock, valued at approximately $625,000.

Other hedge funds also recently modified their holdings of the company. William Blair Investment Management LLC raised its stake in Vericel by 90.3% in the third quarter. William Blair Investment Management LLC now owns 2,210,929 shares of the biotechnology company’s stock valued at $69,578,000 after purchasing an additional 1,048,864 shares in the last quarter. Aberdeen Group plc increased its holdings in Vericel by 159.5% in the 3rd quarter. Aberdeen Group plc now owns 542,866 shares of the biotechnology company’s stock valued at $17,084,000 after buying an additional 333,649 shares during the period. Woodline Partners LP acquired a new position in shares of Vericel in the 3rd quarter valued at approximately $8,409,000. Osterweis Capital Management Inc. acquired a new position in shares of Vericel in the 2nd quarter valued at approximately $9,713,000. Finally, Frontier Capital Management Co. LLC lifted its holdings in shares of Vericel by 74.3% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 398,960 shares of the biotechnology company’s stock worth $16,976,000 after acquiring an additional 170,006 shares during the period.

Analysts Set New Price Targets

VCEL has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Saturday. Leerink Partners reiterated an “outperform” rating and issued a $46.00 price target on shares of Vericel in a research note on Tuesday, March 10th. Truist Financial lowered their price target on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Finally, HC Wainwright upped their price objective on Vericel from $60.00 to $64.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $56.00.

Vericel Trading Up 5.3%

Shares of Vericel stock opened at $32.17 on Wednesday. The firm’s 50 day moving average is $34.95 and its 200 day moving average is $35.77. The firm has a market capitalization of $1.64 billion, a PE ratio of 103.77 and a beta of 1.22. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $45.97.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, February 26th. The biotechnology company reported $0.45 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.45. The firm had revenue of $92.92 million for the quarter, compared to analyst estimates of $92.66 million. Vericel had a net margin of 5.98% and a return on equity of 5.17%. The company’s quarterly revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the business posted $0.38 earnings per share. As a group, research analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current year.

Vericel Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.